IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis.
Su Z, Paulsboe S, Wetter J, Salte K, Kannan A, Mathew S, Horowitz A, Gerstein C, Namovic M, Todorović V, Seagal J, Edelmayer RM, Viner M, Rinaldi L, Zhou L, Leys L, Huang S, Wang L, Sadhukhan R, Honore P, McGaraughty S, Scott VE.
Su Z, et al.
Exp Dermatol. 2019 Feb;28(2):113-120. doi: 10.1111/exd.13841. Epub 2018 Dec 21.
Exp Dermatol. 2019.
PMID: 30417427